166 related articles for article (PubMed ID: 24076765)
1. Immunogenicity and safety of two doses of a non-adjuvanted influenza A H1N1/2009 vaccine in young autoimmune rheumatic diseases patients.
Aikawa NE; Trudes G; Campos LM; Pereira RM; Moraes JC; Ribeiro AC; Miraglia J; Timenetsky Mdo C; Bonfa E; Silva C
Lupus; 2013 Nov; 22(13):1394-8. PubMed ID: 24076765
[TBL] [Abstract][Full Text] [Related]
2. Glucocorticoid: major factor for reduced immunogenicity of 2009 influenza A (H1N1) vaccine in patients with juvenile autoimmune rheumatic disease.
Aikawa NE; Campos LM; Silva CA; Carvalho JF; Saad CG; Trudes G; Duarte A; Miraglia JL; Timenetsky Mdo C; Viana VS; França IL; Bonfa E; Pereira RM
J Rheumatol; 2012 Jan; 39(1):167-73. PubMed ID: 22089462
[TBL] [Abstract][Full Text] [Related]
3. High disease activity: an independent factor for reduced immunogenicity of the pandemic influenza a vaccine in patients with juvenile systemic lupus erythematosus.
Campos LM; Silva CA; Aikawa NE; Jesus AA; Moraes JC; Miraglia J; Ishida MA; Bueno C; Pereira RM; Bonfa E
Arthritis Care Res (Hoboken); 2013 Jul; 65(7):1121-7. PubMed ID: 23818263
[TBL] [Abstract][Full Text] [Related]
4. Antibody response to the non-adjuvanted and adjuvanted influenza A H1N1/09 monovalent vaccines in renal transplant recipients.
Salles MJ; Sens YA; Malafronte P; Souza JF; Vilas Boas LS; Machado CM
Transpl Infect Dis; 2012 Dec; 14(6):564-74. PubMed ID: 22882692
[TBL] [Abstract][Full Text] [Related]
5. Safety and immunogenicity of a monovalent MF59®-adjuvanted A/H1N1 vaccine in HIV-infected children and young adults.
Palma P; Romiti ML; Bernardi S; Pontrelli G; Mora N; Santilli V; Tchidjou HK; Aquilani A; Cotugno N; Alghisi F; Lucidi V; Rossi P; Douagi I
Biologicals; 2012 Mar; 40(2):134-9. PubMed ID: 22261282
[TBL] [Abstract][Full Text] [Related]
6. Immunogenicity and safety of the 2009 non-adjuvanted influenza A/H1N1 vaccine in a large cohort of autoimmune rheumatic diseases.
Saad CG; Borba EF; Aikawa NE; Silva CA; Pereira RM; Calich AL; Moraes JC; Ribeiro AC; Viana VS; Pasoto SG; Carvalho JF; França IL; Guedes LK; Shinjo SK; Sampaio-Barros PD; Caleiro MT; Goncalves CR; Fuller R; Levy-Neto M; Timenetsky Mdo C; Precioso AR; Bonfa E
Ann Rheum Dis; 2011 Jun; 70(6):1068-73. PubMed ID: 21540203
[TBL] [Abstract][Full Text] [Related]
7. Protective effect of A/H1N1 vaccination in immune-mediated disease--a prospectively controlled vaccination study.
Adler S; Krivine A; Weix J; Rozenberg F; Launay O; Huesler J; Guillevin L; Villiger PM
Rheumatology (Oxford); 2012 Apr; 51(4):695-700. PubMed ID: 22171015
[TBL] [Abstract][Full Text] [Related]
8. Effective seroconversion and safety following the pandemic influenza vaccination (anti-H1N1) in patients with juvenile idiopathic arthritis.
Aikawa NE; Campos LM; Goldenstein-Schainberg C; Saad CG; Ribeiro AC; Bueno C; Precioso AR; Timenetsky Mdo C; Silva CA; Bonfá E
Scand J Rheumatol; 2013; 42(1):34-40. PubMed ID: 22992045
[TBL] [Abstract][Full Text] [Related]
9. Identification of antigen and adjuvant doses resulting in optimal immunogenicity and antibody persistence up to 1 year after immunization with a pandemic A/H1N1 influenza vaccine in children 3 to < 9 years of age.
Nassim C; Christensen S; Henry D; Holmes S; Hohenboken M; Kanesa-Thasan N
Pediatr Infect Dis J; 2012 Apr; 31(4):e59-65. PubMed ID: 22418661
[TBL] [Abstract][Full Text] [Related]
10. Dose-range study of MF59-adjuvanted versus nonadjuvanted monovalent A/H1N1 pandemic influenza vaccine in six- to less than thirty-six-month-old children.
Block SL; Ruiz-Palacios GM; Guerrero ML; Beygo J; Sales V; Holmes SJ
Pediatr Infect Dis J; 2012 Jul; 31(7):e92-8. PubMed ID: 22481427
[TBL] [Abstract][Full Text] [Related]
11. Reduced seroprotection after pandemic H1N1 influenza adjuvant-free vaccination in patients with rheumatoid arthritis: implications for clinical practice.
Ribeiro AC; Guedes LK; Moraes JC; Saad CG; Aikawa NE; Calich AL; França IL; Carvalho JF; Sampaio-Barros PD; Goncalves CR; Borba EF; Timenetsky Mdo C; Precioso AR; Duarte A; Bonfa E; Laurindo IM
Ann Rheum Dis; 2011 Dec; 70(12):2144-7. PubMed ID: 21859696
[TBL] [Abstract][Full Text] [Related]
12. Pandemic influenza A H1N1 vaccine in recipients of solid organ transplants: immunogenicity and tolerability outcomes after vero cell derived, non-adjuvanted, whole-virion vaccination.
Lagler H; Wenisch JM; Tobudic S; Gualdoni GA; Rödler S; Rasoul-Rockenschaub S; Jaksch P; Redlberger-Fritz M; Popow-Kraupp T; Burgmann H
Vaccine; 2011 Sep; 29(40):6888-93. PubMed ID: 21803100
[TBL] [Abstract][Full Text] [Related]
13. Immunization with trivalent inactivated influenza vaccine in partially immunized toddlers.
Englund JA; Walter EB; Gbadebo A; Monto AS; Zhu Y; Neuzil KM
Pediatrics; 2006 Sep; 118(3):e579-85. PubMed ID: 16950949
[TBL] [Abstract][Full Text] [Related]
14. Efficient boosting of the antiviral T cell response in B cell-depleted patients with autoimmune rheumatic diseases following influenza vaccination.
Muller RB; Maier R; Hoschler K; Zambon M; Ludewig B; Herrmann M; Schulze-Koops H; von Kempis J
Clin Exp Rheumatol; 2013; 31(5):723-30. PubMed ID: 23806224
[TBL] [Abstract][Full Text] [Related]
15. Immunogenicity, safety and tolerability of MF59-adjuvanted seasonal influenza vaccine in children with juvenile idiopathic arthritis.
Dell'Era L; Corona F; Daleno C; Scala A; Principi N; Esposito S
Vaccine; 2012 Jan; 30(5):936-40. PubMed ID: 22138210
[TBL] [Abstract][Full Text] [Related]
16. Safety and immunogenicity of a 2009 influenza A (H1N1) vaccine in hemodialysis patients.
Lertdumrongluk P; Changsirikulchai S; Limkunakul C; Prachukthum P; Punpiput P; Buppanharun R; Chotpitayasunondh C
Vaccine; 2012 Feb; 30(6):1108-14. PubMed ID: 22178515
[TBL] [Abstract][Full Text] [Related]
17. Immunogenicity and safety of inactivated monovalent 2009 H1N1 influenza A vaccine in immunocompromised children and young adults.
Hakim H; Allison KJ; Van De Velde LA; Li Y; Flynn PM; McCullers JA
Vaccine; 2012 Jan; 30(5):879-85. PubMed ID: 22155630
[TBL] [Abstract][Full Text] [Related]
18. Influenza vaccine immunogenicity in 6- to 23-month-old children: are identical antigens necessary for priming?
Walter EB; Neuzil KM; Zhu Y; Fairchok MP; Gagliano ME; Monto AS; Englund JA
Pediatrics; 2006 Sep; 118(3):e570-8. PubMed ID: 16950948
[TBL] [Abstract][Full Text] [Related]
19. Safety and immunogenicity profile of the concomitant administration of ZOSTAVAX and inactivated influenza vaccine in adults aged 50 and older.
Kerzner B; Murray AV; Cheng E; Ifle R; Harvey PR; Tomlinson M; Barben JL; Rarrick K; Stek JE; Chung MO; Schödel FP; Wang WW; Xu J; Chan IS; Silber JL; Schlienger K
J Am Geriatr Soc; 2007 Oct; 55(10):1499-507. PubMed ID: 17908055
[TBL] [Abstract][Full Text] [Related]
20. Autoimmune response following influenza vaccination in patients with autoimmune inflammatory rheumatic disease.
Perdan-Pirkmajer K; Thallinger GG; Snoj N; Čučnik S; Žigon P; Kveder T; Logar D; Praprotnik S; Tomšič M; Sodin-Semrl S; Ambrožič A
Lupus; 2012 Feb; 21(2):175-83. PubMed ID: 22235050
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
